Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
D2.127 - Rhinovirus Infection in Early Childhood and Risk of Asthma: A Two-Year Follow-Up Study
D2.122 - Impact of Asthma on Outcomes after out-of-hospital cardiac arrest: A nationwide pathway-based analysis, 2013-2023
D2.123 - Temporal Stability of Asthma-Related Out-of-Hospital Cardiac Arrest: A Nationwide SARIMA Analysis of Korean Data From 2013 to 2023
D2.125 - When Severe Asthma Isn’t Asthma: A Case of Humoral Immunodeficiency With Suspicion of Lymphoproliferative Disease
D2.129 - Cardiac onset of EGPA in a postpartum woman: the importance of early diagnosis
D2.131 - Application of a Neural Network Model for Predicting Clinical Outcomes of Acute Bronchitis with Bronchospasm Based on Comorbidities
D2.132 - Prediction of Clinical Outcomes of Acute Bronchitis with Bronchospasm Based on Trigger Factors Using a Neural Network Model
D2.133 - Assessment of growth pattern in wheezing children (3-12 years of age)
D2.326 - The frequency of hereditary α-tryptasemia (HαT) in patenits with insect venom anaphylaxis and in patients with mastocytosis – preliminary results
D2.324 - Anaphylaxis in very early childhood: An ongoing challenge
D2.325 - Desensitization of Olipudase alfa-induced anaphylaxis in a child with chronic neurovisceral acid sphingomyelinase deficiency and ochoa syndrome
D2.327 - Patient and caregiver perspectives on sublingual adrenaline for anaphylaxis: findings from an international survey
D2.329 - Profilin-mediated anaphylaxis with cofactor
D2.331 - An Adult Case of Cofactor-Induced Anaphylaxis Associated with Physical Exercise
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download